<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856413</url>
  </required_header>
  <id_info>
    <org_study_id>BT 987</org_study_id>
    <secondary_id>2012-002516-51</secondary_id>
    <nct_id>NCT01856413</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant</brief_title>
  <acronym>ZEUS</acronym>
  <official_title>An Open, Prospective, Single Arm Study Investigating Efficacy and Safety of Human Hepatitis B Immunoglobulin Zutectra in Liver Transplanted Patients - the ZEUS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AMS Advanced Medical Services GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who receive liver transplantation for hepatitis B virus (HBV) induced liver failure&#xD;
      require longterm therapy to prevent HBV reinfection of the transplanted liver. The approved&#xD;
      preventative treatment is a combination of antihepatitis B immunoglobulin (HBIg) and oral&#xD;
      antiviral medication. In the first 6 months after liver transplantation, patients receive&#xD;
      treatment with intravenous HBIg to maintain blood antihepatitis B (antiHBs)antibody&#xD;
      concentrations above 100 IU/L, the level considered safe for preventing hepatitis B&#xD;
      reinfection.&#xD;
&#xD;
      Zutectra is an HBIg preparation for subcutaneous injection that is approved in the EU for the&#xD;
      'prevention of HBV reinfection in HBV DNA negative patients ≥ 6 months after liver&#xD;
      transplantation for hepatitis B induced liver failure'. The purpose of this study is to show&#xD;
      that earlier subcutaneous HBIg treatment with Zutectra after liver transplantation can&#xD;
      prevent hepatitis B reinfection.&#xD;
&#xD;
      Treatment with subcutaneous HBIg (Zutectra) at home is manageable for the majority of&#xD;
      patients and is more convenient for patients compared to intravenous treatment that must take&#xD;
      place in the hospital setting.&#xD;
&#xD;
      Fourty patients will take part in the study at approximately 19 centres in UK, France, Italy&#xD;
      and Spain. Patients who are eligible for the study will receive treatment with Zutectra for&#xD;
      24 weeks.&#xD;
&#xD;
      During the study, the safety and effectiveness of Zutectra will be assessed by checking for&#xD;
      symptoms of hepatitis B related infection, as well as monitoring blood levels of antiHBs&#xD;
      antibodies and hepatitis B surface antigen (HBsAg).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough levels of serum anti-HBs antibody concentrations</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B related re-infections</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number of all patients with hepatitis B related infections will be assessed by monitoring of clinical signs, liver function and measurement of HBsAg and HBV-DNA.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number of adverse events will be documented including safety laboratory parameters reported as AEs.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Zutectra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zutectra</intervention_name>
    <description>Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.</description>
    <arm_group_label>Zutectra</arm_group_label>
    <other_name>Human hepatitis B Immunoglobulin</other_name>
    <other_name>HBIg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained prior to orthotopic liver transplantation (OLT) -&#xD;
             not more than 3 months before OLT&#xD;
&#xD;
          -  Historical evidence within the last 4 weeks that HBV-DNA is undetectable at time point&#xD;
             of signature of Informed Consent&#xD;
&#xD;
          -  Male and female patients (age 18-75 years)&#xD;
&#xD;
          -  Patients with the diagnosis of liver failure with hepatitis B infection&#xD;
&#xD;
          -  Patients undergoing liver transplantation or re-transplantation&#xD;
&#xD;
          -  HBsAg negative on day 7 or on day 14 after OLT&#xD;
&#xD;
          -  HBV-DNA undetectable at OLT&#xD;
&#xD;
          -  Serum HBs antibody concentration on day 7 or on day 14 after OLT ≥ 400 IU/l&#xD;
&#xD;
          -  Stable patient in a condition which in the opinion of the investigator would permit&#xD;
             safe participation in the study&#xD;
&#xD;
          -  Willingness to fill out patient diary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Re-transplantation due to viral recurrence&#xD;
&#xD;
          -  Positive HIV or HCV test at time of transplantation&#xD;
&#xD;
          -  HBV-DNA positive at OLT&#xD;
&#xD;
          -  Patients having received organs from HBsAg positive donors&#xD;
&#xD;
          -  Pregnancy or unreliable contraceptive measures or lactation period (females only)&#xD;
&#xD;
          -  Known intolerance to immunoglobulins or comparable substances (e.g. vaccination&#xD;
             reaction)&#xD;
&#xD;
          -  Known intolerance to proteins of human origin&#xD;
&#xD;
          -  Participation in another interventional clinical trial within 90 days before entering&#xD;
             the study or during the study and/or previous participation in this study (except&#xD;
             screening failures)&#xD;
&#xD;
          -  Suspicion of drug and/or alcohol abuse&#xD;
&#xD;
          -  Inability or lacking motivation to participate in the study&#xD;
&#xD;
          -  Employee or direct relative of an employee of the CRO, the study site, or Biotest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Samuel, Professeur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Paul Brousse, Centre Hepato-Biliaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Orsola Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera &quot;G. Brutzu&quot; di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>CA 09135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Niguarda Ca Granda-Chirurgia</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedialera Universitaria di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>54124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Tor-Vergata U.O.C.</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molinette Hospital</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Hepatitis B virus re-infection</keyword>
  <keyword>HBV-DNA negative</keyword>
  <keyword>Liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

